190 related articles for article (PubMed ID: 16210843)
1. Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.
Schmidt B
Biol Neonate; 2005; 88(3):208-13. PubMed ID: 16210843
[TBL] [Abstract][Full Text] [Related]
2. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Schmidt B; Anderson PJ; Doyle LW; Dewey D; Grunau RE; Asztalos EV; Davis PG; Tin W; Moddemann D; Solimano A; Ohlsson A; Barrington KJ; Roberts RS;
JAMA; 2012 Jan; 307(3):275-82. PubMed ID: 22253394
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of caffeine therapy for apnea of prematurity.
Schmidt B; Roberts RS; Davis P; Doyle LW; Barrington KJ; Ohlsson A; Solimano A; Tin W;
N Engl J Med; 2007 Nov; 357(19):1893-902. PubMed ID: 17989382
[TBL] [Abstract][Full Text] [Related]
4. Controversies surrounding xanthine therapy.
Millar D; Schmidt B
Semin Neonatol; 2004 Jun; 9(3):239-44. PubMed ID: 15050217
[TBL] [Abstract][Full Text] [Related]
5. Caffeine for apnea of prematurity: a neonatal success story.
Kreutzer K; Bassler D
Neonatology; 2014; 105(4):332-6. PubMed ID: 24931325
[TBL] [Abstract][Full Text] [Related]
6. Early childhood developmental follow-up of infants with GMH/IVH: effect of methylxanthine therapy.
Ment LR; Scott DT; Ehrenkranz RA; Duncan CC
Am J Perinatol; 1985 Jul; 2(3):223-7. PubMed ID: 4015773
[TBL] [Abstract][Full Text] [Related]
7. Caffeine therapy for apnea of prematurity.
Schmidt B; Roberts RS; Davis P; Doyle LW; Barrington KJ; Ohlsson A; Solimano A; Tin W;
N Engl J Med; 2006 May; 354(20):2112-21. PubMed ID: 16707748
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based methylxanthine use in the NICU.
Spitzer AR
Clin Perinatol; 2012 Mar; 39(1):137-48. PubMed ID: 22341542
[TBL] [Abstract][Full Text] [Related]
9. Methylxanthine use for apnea of prematurity among an international cohort of neonatologists.
Abu Jawdeh EG; O'Riordan M; Limrungsikul A; Bandyopadhyay A; Argus BM; Nakad PE; Supapannachart S; Yunis KA; Davis PG; Martin RJ
J Neonatal Perinatal Med; 2013; 6(3):251-6. PubMed ID: 24246598
[TBL] [Abstract][Full Text] [Related]
10. Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Schmidt B; Roberts RS; Anderson PJ; Asztalos EV; Costantini L; Davis PG; Dewey D; D'Ilario J; Doyle LW; Grunau RE; Moddemann D; Nelson H; Ohlsson A; Solimano A; Tin W;
JAMA Pediatr; 2017 Jun; 171(6):564-572. PubMed ID: 28437520
[TBL] [Abstract][Full Text] [Related]
11. Management of apnea in infants.
Kriter KE; Blanchard J
Clin Pharm; 1989 Aug; 8(8):577-87. PubMed ID: 2670399
[TBL] [Abstract][Full Text] [Related]
12. Doxapram versus methylxanthine for apnea in preterm infants.
Henderson-Smart DJ; Steer P
Cochrane Database Syst Rev; 2000; (2):CD000075. PubMed ID: 10796115
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic methylxanthine for prevention of apnoea in preterm infants.
Henderson-Smart DJ; De Paoli AG
Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD000432. PubMed ID: 21154344
[TBL] [Abstract][Full Text] [Related]
14. Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial.
Skouroliakou M; Bacopoulou F; Markantonis SL
J Paediatr Child Health; 2009 Oct; 45(10):587-92. PubMed ID: 19751376
[TBL] [Abstract][Full Text] [Related]
15. Changes in neurodevelopmental outcomes at 18 to 22 months' corrected age among infants of less than 25 weeks' gestational age born in 1993-1999.
Hintz SR; Kendrick DE; Vohr BR; Poole WK; Higgins RD;
Pediatrics; 2005 Jun; 115(6):1645-51. PubMed ID: 15930228
[TBL] [Abstract][Full Text] [Related]
16. Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity.
Sankaran K; Hindmarsh KW; Tan L; Kalapurackal M
Clin Invest Med; 1993 Jun; 16(3):197-203. PubMed ID: 8365047
[TBL] [Abstract][Full Text] [Related]
17. Methylxanthine treatment for apnea in preterm infants.
Henderson-Smart DJ; Steer P
Cochrane Database Syst Rev; 2000; (2):CD000140. PubMed ID: 10796304
[TBL] [Abstract][Full Text] [Related]
18. Doxapram versus methylxanthine for apnea in preterm infants.
Henderson-Smart DJ; Steer P
Cochrane Database Syst Rev; 2000; (4):CD000075. PubMed ID: 11034672
[TBL] [Abstract][Full Text] [Related]
19. Current options in the management of apnea of prematurity.
Bhatia J
Clin Pediatr (Phila); 2000 Jun; 39(6):327-36. PubMed ID: 10879934
[TBL] [Abstract][Full Text] [Related]
20. Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
Khurana S; Shivakumar M; Sujith Kumar Reddy GV; Jayashree P; Ramesh Bhat Y; Lewis LES
J Neonatal Perinatal Med; 2017; 10(4):355-362. PubMed ID: 29286928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
